TY 2136
Alternative Names: TY-2136; TY-2136bLatest Information Update: 28 May 2026
At a glance
- Originator TYK Medicine
- Class Antineoplastics; Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; Protein tyrosine kinase inhibitors; Proteolysis; ROS1 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 28 May 2026 No recent reports of development identified for clinical-Phase-Unknown development in Solid-tumours in China (PO)
- 28 May 2026 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 28 Oct 2024 No recent reports of development identified for preclinical development in Cancer in China (Parenteral)